Acuitas Investments LLC Has $304,000 Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Acuitas Investments LLC lessened its stake in Chimerix, Inc. (NASDAQ:CMRX) by 30.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 316,581 shares of the biopharmaceutical company’s stock after selling 141,210 shares during the quarter. Acuitas Investments LLC’s holdings in Chimerix were worth $304,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. RA Capital Management L.P. acquired a new stake in Chimerix in the 3rd quarter valued at about $6,240,000. Bank of New York Mellon Corp grew its position in shares of Chimerix by 190.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after buying an additional 387,638 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Chimerix by 17.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after buying an additional 72,719 shares during the period. Pale Fire Capital SE acquired a new stake in shares of Chimerix during the 3rd quarter worth approximately $95,000. Finally, Vontobel Holding Ltd. grew its position in shares of Chimerix by 40.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 70,000 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 20,000 shares during the period. Institutional investors and hedge funds own 45.42% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Chimerix in a research report on Friday, March 1st. Wedbush reiterated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research report on Monday, February 12th. Finally, StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Monday, March 4th.

Chimerix Price Performance

CMRX traded up $0.02 during trading on Friday, reaching $0.91. The company had a trading volume of 76,453 shares, compared to its average volume of 389,272. Chimerix, Inc. has a 12 month low of $0.88 and a 12 month high of $1.57. The business’s fifty day moving average price is $1.07 and its 200 day moving average price is $1.00. The company has a market cap of $80.88 million, a P/E ratio of -0.99 and a beta of 1.15.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. As a group, sell-side analysts predict that Chimerix, Inc. will post -0.77 EPS for the current fiscal year.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.